Mindy J. Allport-Settle, MBA
Chief Executive Officer
Ms. Allport-Settle has over 25 years of experience in health care and in the pharmaceutical, medical device, and biotechnology industry.
Her career began when she was a teenager working as an emergency medical technician. Later, she joined the U.S. Navy's advanced hospital corps and attended Wake Forest University's Bowman Gray School of Medicine (specializing in ophthalmology and organ and human tissue procurement). Her educational background includes a Bachelor’s degree from the University of North Carolina and an MBA in Global Management from the University of Phoenix and completion of the corporate governance course series in audit and compensation committees and board effectiveness at Harvard Business School.
Professionally, she has served as a key executive, board member, and consultant for some of the best companies in the pharmaceutical, medical device, and biotechnology industry. At the age of 32, she was the youngest elected member of the Board of Directors of a publicly traded company in North America (Generex Biotechnology, NASDAQ: GNBT) where she served as the Chairman of the Compensation Committee and a member of the Audit and Regulatory Compliance Committees. She also proudly served as a Senate and Congressional lobbyist in the United States for government healthcare reform and the inclusion and promotion of novel therapies in Washington, DC and as a representative of patient protection and commercial integration strategies internationally. She developed the only FDA-recognized and benchmarked quality systems training and development business methodology and has authored more than 30 industry-leading books balancing regulatory requirements, shareholder expectations, patient protection, and community outreach.
Today, Ms. Allport-Settle continues to provide expert guidance in regulatory compliance (both domestic and international law), corporate structuring, restructuring and turnarounds, new drug submissions, research and development, product commercialization, and new business development.